Side-by-side comparison of AI visibility scores, market position, and capabilities
Sana Biotechnology develops engineered cell and gene therapies with fusogen delivery technology to treat serious diseases through in vivo and ex vivo approaches.
Sana Biotechnology is a publicly traded gene therapy company founded in 2018 by veterans of Juno Therapeutics and other leading cell therapy companies. The company is building technologies to repair or replace any gene in any cell, with a particular focus on its proprietary fusogen-based delivery platform that enables engineered cells to fuse with and deliver genetic material to specific target cells in the body. This approach could enable off-the-shelf cell therapies and in vivo gene editing without the need to harvest and engineer patient cells individually. Sana has programs targeting blood cancers, autoimmune diseases, and type 1 diabetes, exploring both in vivo gene delivery and ex vivo engineered cell therapies. The company went public through an IPO in 2021, raising substantial capital to advance its novel platform. Sana has formed research collaborations with academic institutions and pharmaceutical companies to advance specific programs. The company represents the cutting edge of cell and gene therapy with proprietary delivery technologies that could unlock new therapeutic approaches beyond what current viral vector and CRISPR systems enable.
AI quality assurance with insurance-backed warranties from Swiss Re and Greenlight Re; EU AI Act compliance assessments backed by YC and reinsurance partners for high-risk AI deployments.
Armilla AI is a third-party AI quality assurance and warranty company that evaluates AI models for organizations deploying AI in regulated or high-stakes contexts — assessing models against EU AI Act and NIST AI Risk Management Framework requirements for risks including bias, hallucination, robustness failures, and adversarial vulnerabilities, then providing performance guarantees backed by insurance coverage from reinsurers Swiss Re, Greenlight Re, and Chaucer. Founded in Toronto, Canada, Armilla raised $6.81 million total including a C$4.5 million seed round in February 2024 from Mistral Venture Partners, MS&AD Ventures, Y Combinator, and its reinsurance partners.\n\nArmilla's model is unique in the AI governance market — rather than just providing compliance reports, Armilla backs its assessments with insurance warranty products. An enterprise deploying a third-party AI model can purchase an Armilla warranty that pays out if the model performs differently than assessed (fails on bias, accuracy, or robustness metrics), transferring AI performance risk to insurance markets that can price and distribute it. This insurance mechanism creates financial accountability for AI quality claims that audit reports alone don't provide.\n\nIn 2025, Armilla competes in the AI governance, risk, and compliance market with Credo AI, Arthur AI, and AI audit firms for enterprise AI risk assessment and compliance tools. The EU AI Act, fully applicable by August 2025 for high-risk AI systems, is driving enterprise compliance urgency — companies deploying AI in hiring, credit scoring, healthcare, and other regulated contexts need third-party conformity assessments. Armilla's insurance-backed warranty differentiates its offering from pure advisory competitors. The reinsurer backing (Swiss Re, Greenlight Re, Chaucer) provides both capital credibility and distribution through insurance broker channels. The 2025 strategy focuses on growing EU AI Act compliance assessments and expanding the warranty product coverage to more AI deployment use cases.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.